<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992859</url>
  </required_header>
  <id_info>
    <org_study_id>CIMPAX BREAST</org_study_id>
    <nct_id>NCT03992859</nct_id>
  </id_info>
  <brief_title>Continuous Serrates Plane Block in Axillary Dissection</brief_title>
  <official_title>Continuous Serratus Plane Block Added to PECS II vs PECS II Alone for Post Operative Analgesia After Axillary Dissection in Breast Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergone to axillary dissection during breast surgery with a PECS I, II block will
      be randomized to receive either a serratus plane continuous local anesthetic infusion through
      a multiple hole catheter or nothing. Both groups will receive a patient controlled analgesia
      with morphine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      84 patients ASA I-III undergoing breast surgery with axillary dissection after modified PECS
      II block as described by Blanco et al. with Ropivacaine 0.37% 30 ml. General anesthesia with
      remifentanil 0.1 mcg/Kg/min and Propofol 1.5-2 mg/Kg to facilitate endotracheal intubation
      will provide for all patients, and maintained with Desflurane and Remifentanil infusion. In
      case of axillary dissection patient will be randomized to receive either a serratus plane
      continuous local anesthetic infusion through a multiple hole catheter or nothing. Both groups
      will receive as intraoperative analgesia 1 g Acetaminophene ev 30 minute before the end of
      the surgery and 1g. 8h-1 postoperative associated to a patient controlled analgesia with
      morphine. PCA will set up as follow: bolus 1 mg, lock-out 6 minute, max 20 mg/4h. In the
      serratus group 10 ml of Ropivacaine 0.5% before fascial closure and a continuous infusion of
      12 ml/h of Ropivacaine 0.2% will be provide.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">June 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>12-48 hours</time_frame>
    <description>A 70% reduction in morphine consumption in the continuous serratus plane block over control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>persistent post-surgical pain: numerical rating scale</measure>
    <time_frame>3-6 months</time_frame>
    <description>a numerical rating scale (0-10, 0= no pain, 10 = worst imaginable pain),&gt; 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>serratus catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous serratus plane block: Ropivacaine 0.2% infusion through a multiple hole catheter (C-Cat Cimpax Denmark)at a fixed dose of 12 ml/h and a multimodal analgesia with acetaminophen and a PCA of morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-operative multimodal analgesia with Acetaminophen and PCA of Morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous serratus plane block</intervention_name>
    <description>Peripheral nerve catheter placed by the surgeon at the end of surgery</description>
    <arm_group_label>serratus catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18

          -  breast surgery

          -  informed consent

        Exclusion Criteria:

          -  ASA &gt;3

          -  allergy to local anesthetic

          -  opioid administration in the last month

          -  patient refusal
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico bizzarri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arcispedale Santa Maria Nuova-IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico bizzarri</last_name>
    <phone>3478351913</phone>
    <email>federicotommaso.bizzarri@ausl.re.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federico bizzarri</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ausl-Irccs Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42120</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>federico bizzarri, MD</last_name>
      <email>federicotommaso.bizzarri@ausl.re.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcispedale Santa Maria Nuova-IRCCS</investigator_affiliation>
    <investigator_full_name>Federico Tommaso Bizzarri</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>regional anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

